Disc Medicine Advances DISC-3405 in Polycythemia Vera
WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...
myelofibrosis
Advertisement
Ipsen Completes Kartos Acquisition to Expand Oncology Pipeline
Paris, France | August 21, 2026 Ipsen announced the completion of its acquisition of Kartos Therapeutics, strengthening its late-stage...
Damora Therapeutics Initiates Phase 1/1b Trial of DMR-001
WALTHAM, Massachusetts, August 5, 2026 Damora Therapeutics, Inc. announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial...
Damora Therapeutics Launches Phase 1 Trial of DMR-001
WALTHAM, Mass., Aug. 5, 2026 Damora Therapeutics, Inc. has announced the initiation of the global Phase 1/1b CLARITY-101 clinical...
Karyopharm Eyes Accelerated FDA Approval for Selinexor
NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...
Advertisements
Syndax Unveils SNDX-4321, Expands Pipeline
NEW YORK, July 14, 2026 Syndax Pharmaceuticals unveiled two new pipeline candidates during its 2026 R&D Event, expanding its...
Ipsen and Kartos Therapeutics Sign $1.75B Acquisition Deal
PARIS, France & REDWOOD CITY, Calif., June 29, 2026 Ipsen has announced a definitive agreement to acquire Kartos Therapeutics,...
FDA Clears Dexcom Stelo OTC CGM for Children
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
Menarini Reports Positive Phase 3 SENTRY Data at EHA
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
Advertisement
